Abbreviated Name

LUNG REF

Lead Investigator

Bigbee, William L. — University of Pittsburgh Cancer Institute

Coordinating Investigator

Zheng, Yingye — Fred Hutchinson Cancer Center

Involved Investigators

• Grogan, Eric — Vanderbilt -Ingram Cancer Center
• Pass, Harvey Ira — New York University School of Medicine
• Hanash, Samir — The University of Texas MD Anderson Cancer Center
• Diaz-Mayoral, Norma — Frederick National Laboratory for Cancer Research
• Srivastava, Sudhir — National Cancer Institute
• Dubinett, Steve — University of California Los Angeles
• Jett, James R — Mayo Clinic
• Bigbee, William L. — University of Pittsburgh Cancer Institute
• Spitz, Margaret R. — The University of Texas MD Anderson Cancer Center
• Tockman, Melvyn S. — H. Lee Moffitt Cancer Center
• Califano, Joseph — Johns Hopkins Medical Institute
• Rom, William — New York University School of Medicine
• Ujhazy, Peter — National Cancer Institute
• Franklin, Wilbur Alan — University of Colorado Health Science Center
• Zheng, Yingye — Fred Hutchinson Cancer Center

Abstract

The NCI/EDRN/SPORE Lung Cancer Biomarkers Group (LCBG) began its activities back in November 2004 and developed clear objectives and strategies on how to begin validating a series of candidate biomarkers for the early detection of lung cancer. The initial goal of the LCBG is to develop the requisite sample resources to validate serum/plasma biomarkers for the early diagnosis of lung cancer. Researchers may use these resources and process for continued biomarker refinement but this is not the primary activity of the LCBG.

Aims

Our specific goals include: 1.   Develop reference case/control serum/plasma sets held in a NCI repository and make these samples available to the research community. 2.   Define, refine and validate blood-based biomarkers for lung cancer. 3.   Test reproducibility of biomarkers within and across institutions. 4.   Test reproducibility of biomarkers within and across analytical platforms.

Analytic Method

N/A

Outcome

The NCI/EDRN/SPORE Lung Cancer Biomarkers Group (LCBG) began its activities back in November 2004 and developed clear objectives and strategies on how to begin validating a series of candidate biomarkers for the early detection of lung cancer. The initial goal of the LCBG is to develop the requisite sample resources to validate serum/plasma biomarkers for the early diagnosis of lung cancer. Researchers may use these resources and process for continued biomarker refinement but this is not the primary activity of the LCBG.

Publications

• No publications available at this time for this protocol.

Biomarkers

• No biomarkers available at this time for this protocol.

Data Collections

• No data collections available at this time for this protocol.

 Team Project

Start Date

Mar 18 2009

Estimated Finish Date

Mar 18 2010

Finish Date

Sep 30 2010

Protocol ID

115

Protocol Type

Reference Set

Fields of Research

• Other

Collaborative Group

Lung and Upper Aerodigestive Cancers Research Group

Cancer Types

• Malignant neoplasm of bronchus and lung